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Abstract (200) 33 
Recently, excellent treatment outcomes have been reported for patients with 34 
multidrug/extensively drug-resistant tuberculosis (M/XDR-TB) in settings where optimal 35 
resources for individualized therapy are available. We ascertained whether differences in 36 
treatment responses still exist in patients with M/XDR-TB compared to patients with non-37 
M/XDR-TB. 38 
Patients with tuberculosis were prospectively enrolled between March 2013 and March 39 
2016 at five hospitals in Germany. Treatment was conducted following current guidelines 40 
and individualized on the basis of comprehensive drug-resistance testing. Two-months and 41 
6-months sputum-smear and sputum-culture conversion rates were assessed. A clinical and 42 
a radiological score were used to assess the response to anti-tuberculosis therapy. 43 
Non-M/XDR-TB (n=29) and M/XDR-TB (n=46) patients showed similar rates of 44 
microbiological conversion (2-months smear-conversion-rate 90% vs. 78% and culture-45 
conversion-rate 67% versus 61%, respectively; time-to-smear/culture-conversion 19 (IQR10-46 
32) vs. 31 (IQR14-56) (p=0.066), and 39 (IQR17-67) vs. 39 (IQR6-85) days (p=0.191), 47 
respectively). Both clinical and radiological scores declined after the introduction of anti-48 
tuberculosis therapy. There were no significant differences of scores between the groups 49 
until 6 months of therapy. 50 
Under optimal clinical conditions with availability of novel diagnostics and a wide range of 51 
therapeutic options for individualized therapy, patients with M/XDR-TB achieve 6 month 52 
culture conversion rates that are compatible to patients with non-M/XDR-TB. 53 
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Introduction 54 
Tuberculosis (TB) is the leading cause of mortality attributed to a single microbial pathogen 55 
worldwide (1, 2). The World Health Organization (WHO) estimates that more than 10 million 56 
people developed active TB in 2016, the highest ever-estimated number of affected patients 57 
in history. The emergence of multidrug-resistant (MDR; defined by bacillary resistance 58 
against rifampicin and isoniazid) and extensively drug-resistant (XDR; MDR plus resistance 59 
against at least one fluoroquinolone and one second-line injectable drug) TB is especially 60 
worrisome. M/XDR-TB has been related to high treatment costs, increased frequency of 61 
adverse drug-events, and poor therapy outcomes (1, 3-7). At the recent meeting of the G20 62 
leaders in Hamburg, Germany, combatting antimicrobial resistance, including drug-resistant 63 
TB, has been identified as a global priority (8). 64 
 65 
Currently, the World Health Organization (WHO) recommends a therapy duration for 66 
M/XDR-TB patients of at least 20 months unless specific criteria allow for a standardized 67 
short course MDR-TB regimen over 9-12 months (3, 9-13). Only approximately 50% of 68 
M/XDR-TB patients in Europe attain favorable outcomes. In contrast, in settings where 69 
individualized treatment can be provided, successful treatment outcomes are usually 70 
observed (3, 4, 14-16). The concept of individualized therapy targets the special demands of 71 
every host and pathogen leading to tailored treatment in every patient (17). Currently, new 72 
diagnostic methods and novel drugs have been introduced that may improve treatment 73 
outcomes (17-20). 74 
 75 
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Based on these observations, we aimed to compare 6-months culture conversion, as early 76 
indicators of treatment outcomes, in M/XDR-TB and non-M/XDR-TB patients from settings 77 
where optimal resources are available. Additionally, we evaluated a clinical and a 78 
radiological scoring system (21). 79 
 80 
Study population and methods 81 
Between March 2013 and March 2016 patients with TB identified by sputum GeneXpert 82 
MTB/RIF test (Cepheid, Sunnyvale, USA) were prospectively enrolled at the Medical Clinic, 83 
Research Center Borstel; Karl-Hansen-Klinik, Bad Lippspringe; Sankt Katharinen-84 
Krankenhaus, Frankfurt; Thoraxklinik-Heidelberg, Heidelberg; Asklepios Fachkliniken 85 
München-Gauting, Munich in Germany. Patients with M/XDR-TB were enrolled 86 
consecutively at all centers after satisfying in- and exclusion criteria, and providing written 87 
informed consent. Patients with non-MDR-TB were also recruited if inclusion criteria were 88 
met or exclusion criteria were not met and they agreed with participation. Athough patients 89 
with non-MDR-TB were not strictly recruited consecutively at all centers, selection was not 90 
based on patients characteristics but depended on staff availability. Individuals were 91 
excluded if they were less than 18 years of age, not legally able to provide consent or if they 92 
were infected with HIV. All patients gave written informed consent. Following approval at 93 
the Ethics Committee of the University of Lübeck (AZ 12-233), Germany, the study protocol 94 
was approved at the local Ethic Committees of all participating centers. 95 
 96 
Following rapid molecular identification of rifampicin resistance by GeneXpert, sputum 97 
samples underwent second-line molecular drug resistance testing of M. tuberculosis by line-98 
probe-assays (GenoType MTBDRplus and MTBDRsl Hain Lifesciences, Nehren, Germany). 99 
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Sputum samples also underwent phenotypic drug susceptibility testing according to WHO 100 
recommendations at a certified and quality controlled microbiology laboratory (WHO 101 
Supranational Reference Laboratory Network). During the in-patient period, sputum samples 102 
were collected for smear microscopy and culture on a weekly basis. After discharge, sputum 103 
was collected as part of routine follow-up visits. Demographic information was collected on 104 
study enrolment. 105 
 106 
A novel clinical score consisting of self-reported and objectively observed items (maximum 107 
score of 30 points), which is based on a published scoring system (22), was recorded by a 108 
physician during the clinical visits. Self-reported items were cough, hemoptysis, dyspnea, 109 
thoracic pain, night sweats, loss of weight, and inability to walk (each one point). The 110 
examined score items (if not indicated differently, one point each) consisted of axillary body 111 
temperature (>37°= one point, >38°= two points), impaired consciousness, focal neurologic 112 
deficits, body mass index (kg/m2; <20= one point, <18= two points, <16= three points), 113 
middle upper arm circumference (mm; <220= one point, <200= two points), capillary filling 114 
time >2 sec., cyanosis, tachycardia (beats per minute; >100= one point, >120=two points), 115 
blood pressure <90 mmHg systolic or <60 mmHg diastolic, lung crackles, tachypnea (per 116 
minute; >20= one point, >25= two points, >30= three points), oxygen saturation (%; <90= 117 
one point, < 87= 2 points), and age above 65 (one point). 118 
 119 
Chest X-rays were performed at clinically relevant time-points during the course of 120 
treatment. The extent of pulmonary TB was assessed by a validated scoring system (21). In 121 
brief, the percentage of TB-associated infiltrations in chest X-rays was assessed and 40 122 
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points were added to the score if cavities were present (max. 140 points). An experienced 123 
chest physician scored the chest X-rays. 124 
 125 
Time to sputum culture conversion (TCC) and smear conversion (TSC) were defined as the 126 
time (in days) from the initiation of effective anti-TB therapy to the date of the first negative 127 
culture or sputum smear (date of collection). Therapy was deemed effective according to 128 
DST results. 129 
 130 
Individualized anti-TB drug regimens for patients with M/XDR-TB were designed using 131 
current therapy recommendations, and results of molecular and phenotypic drug 132 
susceptibility testing (10, 11, 23, 24). Patients with non-M/XDR TB were treated following 133 
national TB guidelines (25). 134 
 135 
Smear and culture conversion for the first six months after treatment initiation were 136 
evaluated using survival analysis, and compared with survival curves for the two cohorts by a 137 
logrank test. Kaplan-Meier estimates derived from the survival curves for smear and culture 138 
conversion at month 2 and month 6, and the medium time to smear or culture conversion 139 
are reported. Measured clinical score and change in radiological score were assessed by 140 
mean and 95% confidence interval at a priori time points. All statistical tests used a two-141 
sided alpha-value of 0.05 to assess statistical significance. Analyses were performed using 142 
STATA (Version 14, StataCorp LLC, College Station, Texas, USA). 143 
 144 
Results 145 
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Seventy-five patients were enrolled, of whom 46 were infected with non-M/XDR and 29 with 146 
M/XDR-TB strains. Patients´ characteristics are displayed in table 1. Of the 29 patients with 147 
M/XDR-TB, eight patients were infected with an XDR strain of M. tuberculosis. Median age 148 
was higher in patients with non-M/XDR-TB compared to M/XDR-TB patients (43.0 years (IQR 149 
31.0 – 58.0) vs. 36.0 years (IQR 30.0 – 41.0)). Sex distribution (non-M/XDR-TB: males 30 150 
(65.2%) vs. M/XDR-TB: males 16 (62.1%)) and median BMI values (non-M/XDR-TB: 21.1 151 
kg/m2 (IQR 18.1 – 24.8 vs. M/XDR-TB: 21.7 kg/m2 (19.4 - 25.4)) were similar in both patient 152 
groups. 153 
 154 
The results of available DST results are shown in table 2. Among the 46 patients with non-155 
M/XDR-TB two patients had isoniazid mono-resistance. No further drug-resistances to first-156 
line drugs (ethambutol and pyrazinamide tested in 44 strains) nor second-line drugs 157 
(prothionamide, ofloxacin, and capreomycin tested in 11 strains) were detected in this 158 
group. Strains from patients with M/XDR-TB showed high frequencies of first-line drug 159 
resistance; 18/27 (66.7%) for ethambutol, 22/27 (81.5%) pyrazinamide. Additionally, 160 
resistance was present in M/XDR-TB strains to capreomycin 10/29 (34.5%), amikacin 7/29 161 
(24.1%), ofloxacin 9/27 (33.3%), prothionamide 14/27 (51.9%), para-amino-salicylic acid 1/27 162 
(3.7%) and linezolid 1/27 (3.7%). None of the M/XDR-TB strains were resistant to  163 
terizidone/cycloserin. 164 
 165 
The starting therapy regimens are shown in table 3. Most M/XDR-TB patients receiving 166 
fluoroquinolones were treated with moxifloxacin 18/22 (81.8%) and only 4/22 (18.2%) 167 
received levofloxacin. Of 21/29 (72.4%) M/XDR-TB patients who were treated with second-168 
line injectable drugs 14/21 (66.7%) patients were given capreomycin and 7/21 (33.3%) 169 
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amikacin. Only 3/29 (10.4%) M/XDR-TB patients were treated with regimens containing 170 
bedaquiline or delamanid. 171 
Patients with M/XDR-TB had a slightly lower Kaplan-Meier estimate for smear conversion 172 
compared to patients with non-M/XDR-TB at month two (78% versus 90%, respectively), and 173 
at month six (93% and 96%, respectively, p=0.004; table 4 and figure 1A). Such a difference 174 
was not seen for culture conversion (figure 1B and table 4), where Kaplan-Meier estimates 175 
were 61% and 67%, respectively at month two, and 95% and 97%, respectively, at month six 176 
(p = 0.191). The median time to smear conversion was 31 days (IQR: 14-56) and 19 days 177 
(IQR: 10-32) for patient with non-M/XDR-TB and M/XDR-TB respectively. Time to culture 178 
conversion was with 39 days, identical in both groups.  179 
The mean clinical scores before treatment initiation were higher in patients with non-180 
M/XDR-TB TB than in patients with M/XDR-TB (5.8 (95%CI 3.5–7.4) vs. 4.8 (95%CI 3.6–5.6)) 181 
with a decline of mean scores in both cohorts after therapy initiation (online appendix table 182 
1 and figure 2). There were no obvious differences in the development of the clinical score 183 
between treatment initiation and month 6. 184 
The radiological extent of disease evaluated using the Ralph score at baseline showed similar 185 
values in both groups (mean 58.8 vs. 52.1 points; online appendix table 1 and figure 3). 186 
Although there was a slight increase of pulmonary infiltrations in the non-M/XDR-TB cohort 187 
after treatment start, the score values declined over the time of treatment. Here, the 188 
radiological scores of patients with M/XDR-TB remained at higher values, which was mainly 189 
explained by a higher frequency of the persistence of cavitary lesions in the chest X-rays. A 190 
higher proportion of patients with M/XDR-TB previously had TB and thus prior lung damage, 191 
which would explain more extensive infiltrations.   192 
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Discussion 193 
We compared early treatment response in a prospective cohort of patients with M/XDR-TB 194 
and patients with non-M/XDR-TB in Germany, a country where unrestricted diagnostic and 195 
therapeutic resources for the management of patients with M/XDR-TB are available. Six-196 
months culture conversion was similar for patients with non-MDR-TB and M/XDR-TB, which 197 
could suggest a high chance of cure for patients with M/XDR-TB. 198 
 199 
Our findings are in line with published data showing that the 6-months culture conversion 200 
status is indicative for sustained treatment response in patients with M/XDR-TB (14, 26). 201 
Using 6-months culture conversion status and a one-year follow-up after therapy completion 202 
as markers for therapy outcome has also been suggested in a recently published study (14). 203 
Although the 2-months culture conversion status has been evaluated as a surrogate for 204 
treatment response in clinical trials evaluating novel anti-TB drugs, such as bedaquiline and 205 
delamanid (27, 28), treatment outcomes are better correlated to the 6-months culture 206 
conversion status (29). Six-months culture-conversion status was similar in both groups 207 
(table 4). In the present study, the 2-months culture conversion rates of our M/XDR-TB 208 
patients undergoing tailored treatment regimens on the basis of comprehensive drug 209 
susceptibility testing exceeded the rates from trials presenting promising novel drugs with 210 
excellent therapy results (27, 28, 30). 211 
 212 
Standardized therapy regimens as presented by the “Bangladesh” regimen have yielded 213 
excellent outcomes in specific settings with low frequencies of second-line drug resistance 214 
(30). Based on these results the WHO made a conditional recommendation for a “shorter 215 
course regimen” for the treatment of MDR-TB (9). However, only very few patients from the 216 
European region may be eligible for this regimen due to high frequencies of second-line drug 217 
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resistance (13, 31, 32), which may lead to treatment failure and acquisition of additional 218 
drug resistance (33). The low eligibility of patients from this setting is also reflected by our 219 
study where high frequencies of first and second-line drug resistance were identified. This 220 
strongly indicates that standard treatment regimens could lead to the emergence of 221 
additional drug resistance due to inadequate therapy.  222 
 223 
This study also showed that tailored treatment regimens in our study were highly variable. In 224 
fact, such individualized therapy regimens were shown to lead to very high frequencies of 225 
favorable treatment outcomes in an Austrian cohort (15). In contrast to patients who 226 
received standardized treatment regimens, higher frequencies of cure for patients with 227 
MDR-TB from the European region were found with individualized treatment regimens in a 228 
large European multicenter cohort (Günther et al. submitted). Higher frequencies of 229 
treatment success in patients receiving individualized therapy were also shown by large 230 
meta-analyses comparing treatment results of patients with MDR-TB under standardized or 231 
individualized regimens (16, 34).  232 
 233 
We also evaluated the performance of an existing radiological score using chest X-rays and a 234 
novel clinical score to further characterize the effect of treatment on an individual basis (21, 235 
35). The items included in the clinical score were based on a published scoring system, which 236 
was shown to predict mortality and treatment response in African cohorts (22, 36, 37). 237 
Although we were able to show declining clinical and radiological scores after therapy 238 
initiation (figure 3 and 4, online appendix table 1), our intention to correlate the scores’ 239 
trajectories with the established markers such as time to culture or to smear conversion, and 240 
2- or 6 month culture conversion status failed, given the almost uniformly high frequency of 241 
conversion in a relatively small cohort. Unfortunately, the small number of patients 242 
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precluded data reduction strategies like principal component analysis to evaluate the clinical 243 
score. The decline in radiological score observed in our study was slow probably due to 244 
persistence of cavitary lesions, which are slower to resolve, and in the presence of an 245 
adequate clinical and microbiological response. Nevertheless, these or other clinically 246 
derived scores may serve as alternative end-points for future biomarker validation and 247 
should be reconsidered in future studies (38). 248 
 249 
Although the relatively low number of patients evaluated limits our study, a very close 250 
microbiological and clinical monitoring and the observations from clinical and radiological 251 
scores strengthens our findings. 252 
 253 
In conclusion, under optimal clinical conditions with availability of novel diagnostics and 254 
individualized therapy, patients with M/XDR-TB can achieve 6-months culture conversion, 255 
the frequency of which is similar to that of to patients with non-M/XDR-TB. This personalized 256 
approach to therapy may have the potential to yield high frequencies of cure. The clinical 257 
and radiological scores should be further evaluated with the aim to identify and validate 258 
markers to individualize the duration of therapy. 259 
 260 
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TABLES 265 
Table 1. Clinical characteristics of patients with non-MDR-TB and M/XDR-TB. 266 
 Non-M/XDR* M/XDR Total 
 N = 46 N = 29 N = 75 
 n % n % n % 
Sex       
Male 30 65.2 18 62.1 48 64.0 
       
Age, median (IQR) 43.0 31.0 – 58.0 36.0 30.0 – 41.0 39.0 31.0 – 56.0 
BMI, median (IQR) 21.1 18.1 – 24.8 21.7 19.4 - 25.4 21.2 18.3 – 25.4 
TB contact       
No 21 45.7 9 31.0 30 40.0 
Yes 6 13.0 4 13.8 10 13.3 
missing 19 41.3 16 55.2 35 46.7 
BCG       
Yes 13 28.3 16 55.2 29 38.7 
missing 28 60.9 12 41.4 40 53.3 
TB type       
not previously treated for TB 35 76.1 18 62.1 53 70.7 
Relapse 6 13.0 6 20.7 12 16.0 
Failure 0 0.0 1 3.4 1 1.3 
Return from default 1 2.2 1 3.4 2 2.7 
missing 4 8.7 3 10.3 7 9.3 
Previous TB       
       
Yes 7 15.2 10 34.5 17 22.7 
missing 14 30.4 4 13.8 18 24.0 
Diabetes       
Yes 4 8.7 2 6.9 6 8.0 
missing 19 41.3 5 17.2 24 32.0 
Hepatitis B       
Yes 3 6.5 1 3.4 4 5.3 
missing 25 54.3 12 41.4 37 49.3 
Hepatitis C       
       
Yes 2 4.3 3 10.3 5 6.7 
missing 25 54.3 11 37.9 36 48.0 
*44 patients with pan-drug susceptible TB and 2 patients with isoniazid mono-resistance 267 
  268 
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Table 2. Results of Mycobacterium tuberculosis phenotypic drug susceptibility testing from 269 
patients with non-M/XDR and M/XDR. 270 
 Non M/XDR* M/XDR 
 N = 46 N = 29 
Drug Tested Resistant Tested Resistant 
 N % N % N % N % 
H 45 97.8 2 4.4 27 93.1 27 100 
R 46 100 0 0.0 29 100 29 100 
E 44 95.7 0 0.0 27 93.1 18 66.7 
Z 44 95.7   27 93.1 22 81.5 
L     10 34.5 9 90.0 
M     16 55.2 9 56.3 
O 11 23.9 0 0.0 27 93.1 9 33.3 
S     16 55.2 12 75.0 
A     29 100 7 24.1 
C 11 23.9 0 0.0 29 100 10 34.5 
K     8 27.6 2 25.0 
P 11 23.9 0 0.0 27 93.1 14 51.9 
T     26 89.7 0 0.0 
c     1 3.4 1 100 
l     27 93.1 1 3.7 
p     27 93.1 1 3.7 
m     1 3.4 1 100 
a     1 3.4 1 100 
*44 patients with pan-drug susceptible TB and 2 patients with isoniazid mono-resistance 271 
H: isoniazid; R: rifampicin; Z: pyrazinamid; E: ethambutol; O: ofloxacin; M: moxifloxacin; L: levofloxacin; S: 272 
streptomycin; C: capreomycin; A: amikacin; K: kanamycin; P: protionamide; T: terizidone/cycloserin; l: linezolid; 273 
c: clofazamin; p: para-amino-salicylic acid; m: meropenem; a: amoxicillin/clavulanic acid. 274 
  275 
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Table 3. Starting regimens in patients with non-MDR-TB and M/XDR-TB. 276 
Drugs Non-M/XDR* M/XDR 
HRZE – OML – SCAK – PTlc – BD - pma   
XXXX - ... - .... - .... - .. - ... 34 0 
XXXX - ... - .... - ..X. - .. - X.. 1 0 
XXX. - ... - .... - .... - .. - ... 6 0 
XX.X - ... - X... - .... - .. - ... 2 0 
XX.X - ... - .... - .... - .. - ... 1 0 
X..X - ... - .... - .... - .. - ... 1 0 
.XXX - .X. - .... - .... - .. - ... 1 0 
.X.. - .X. - .X.. - XX.. - .. - ... 0 1 
..XX - .X. - .X.. - XX.. - .. - ... 0 1 
..XX - .X. - .X.. - XX.. - .. - ... 0 1 
..XX - .X. - ..X. - XX.. - .. - ... 0 1 
..XX - ..X - ..X. - .XX. - .. - ... 0 1 
..X. - .X. - .X.. - XXX. - .. - ... 0 1 
..X. - .X. - .X.. - XX.. - .. - ... 0 2 
..X. - .X. - .X.. - .X.. - .. - ... 0 1 
..X. - .X. - ..X. - ..XX - .. - ... 0 1 
..X. - ..X - ..X. - .XXX - .. - ... 0 1 
..X. - ... - .X.. - .XX. - .. - ... 0 1 
..X. - ... - ..X. - .X.X - .. – XXX 0 1 
..X. - ... - .... - .X.X - .. - XXX 0 1 
...X - .X. - .X.. - XX.X - .. - ... 0 1 
...X - .X. - .X.. - XX.. - .. - ... 0 1 
...X - .X. - .X.. - X... - .. - ... 0 1 
...X - ..X - .... - XXX. - .. - ... 0 1 
.... - .X. - .X.. - .XXX - .. - X.. 0 1 
...X - ... - ..X. - .XX. - X. - ... 0 1 
.... - .X. - .X.. - .XX. - .. - X.. 0 1 
.... - .X. - .X.. - .X.. - .. - X.. 0 1 
.... - .X. - ..X. - .XX. - .. - X.. 0 1 
.... - .X. - .... - XXXX - .. - ... 0 1 
.... - ..X - .... - .XX. - X. - ... 0 1 
.... - ... - .... - .XXX - X. - .XX 0 2 
.... - ... - .... - .XXX - .. - XXX 0 1 
.... - ... - .... - .XX. - .. - ... 0 1 
*44 patients with pan-drug susceptible TB and 2 patients with isoniazid mono-resistance 277 
“.” indicates if drug was not used and “X” if drug was used; H: isoniazid; R: rifampicin; Z: pyrazinamid; E: 278 
ethambutol; O: ofloxacin; M: moxifloxacin; L: levofloxacin; S: streptomycin; C: capreomycin; A: amikacin; K: 279 
kanamycin; P: protionamide; T: terizidone/cycloserin; l: linezolid; c: clofazamin; B: bedaquiline; D: delamanid; p: 280 
PAS; m: meropenem; a: amoxicillin/clavulanic acid. 281 
 282 
 283 
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Table 4. Percentage of patients with M. tuberculosis culture and smear conversion at month 284 
2 and 6 after therapy initiation and median time to conversion with interquartile range for 285 
patients with non-M/XDR-TB and M/XDR-TB. 286 
  Non-M/XDR* M/XDR p-
value# 
  KM estimate (%) Time to 
conversion 
KM estimate (%) Time to 
conversion 
  
  Month 
2 
Month 
6 
Median IQR Month 
2 
Month 
6 
Median IQR   
                    
  % % Days Days % % Days Days   
Smear 
conversion 
90 96 19 10 - 32 78 93 31 14 - 56 0.044 
Culture 
conversion 
67 97 39 17 - 67 61 95 39 6 - 85 0.191 
 *44 patients with pan-drug susceptible TB and 2 patients with isoniazid mono-resistance 287 
#Derived from Log-rank test. 288 
  289 
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Figure 1A and 1B.  310 
A. Kaplan-Meier estimates for the first negative sputum smear microscopy in patients with 311 
non-M/XDR-TB (grey line) and M/XDR-TB (black line) after therapy initiation. Below the X-312 
axis, the number at risk is shown. B. Kaplan-Meier estimates for the first negative sputum 313 
culture (liquid and solid) in patients with non-M/XDR-TB (grey line) and M/XDR-TB (black 314 
line) after therapy initiation. Below the X-axis, the number at risk is shown. 315 
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Figure 2. Mean clinical scores (Y-axis) during the course of therapy (X-axis, months) for 329 
patients with susceptible (gray line) and M/XDR-TB (black line) with 95% confidence interval 330 
(dashed lines). 331 
  332 
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 333 
Figure 3. Mean change of radiological (Ralph) scores (Y-axis, %) in the course of therapy (X-334 
axis, months) for patients with susceptible (grey line) and M/XDR-TB (black line) with 95% 335 
confidence interval (dashed lines). 336 
  337 
-8
0
-6
0
-4
0
-2
0
0
2
0
C
h
a
n
g
e
 (
%
)
 
0 1 2 4 6
 
Month
non-M/XDR M/XDR
Mean change in Ralph scores
20 
 
REFERENCES 338 
 339 
1. World Health Organization. Global tuberculosis report 2016. Geneva, 340 
Switzerland2016. 341 
2. Global Burden Diseases Study- Mortality Causes of Death Collaborators. Global, 342 
regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 343 
249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease 344 
Study 2015. Lancet. 2016;388(10053):1459-544. 345 
3. European Centre for Disease Prevention and Control (ECDC). Tuberculosis 346 
surveillance and monitoring in Europe 2016. Stockholm, Sweden: European Centre for 347 
Disease Prevention and Control, 2017. 348 
4. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug 349 
resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual 350 
patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. 351 
5. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to 352 
fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB 353 
outcomes. Eur Respir J. 2013;42(1):156-68. 354 
6. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, et al. Efficacy, 355 
safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: 356 
systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430-42. 357 
7. Günther G, Gomez GB, Lange C, Rupert S, van Leth F, Tbnet. Availability, price and 358 
affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J. 359 
2015;45(4):1081-8. 360 
8. G20 Leaders ́ Declaration. Shaping an interconnected world. In: G20, editor. 361 
Hamburg2017. 362 
9. World Health Organization. Rapid diagnostic test and shorter, cheaper treatment 363 
signal new hope for multidrug-resistant tuberculosis patients Geneva, Switzerland2016 364 
[cited 2016 29.7.2016]. Available from: 365 
http://www.who.int/mediacentre/news/releases/2016/multidrug-resistant-tuberculosis/en/. 366 
10. World Health Organization. Guidelines for the programmatic management of drug-367 
resistant tuberculosis 2016 update. Geneva, Switzerland: WHO Library Cataloguing-in-368 
Publication Data; 2016. 369 
11. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, et al. 370 
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in 371 
Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23-63. 372 
12. Balabanova Y, Fiebig L, Ignatyeva O, Riekstina V, Danilovits M, Jaama K, et al. 373 
Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a 374 
rule? Thorax. 2017. 375 
13. Lange C, Duarte R, Frechet-Jachym M, Günther G, Guglielmetti L, Olaru ID, et al. 376 
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am 377 
J Respir Crit Care Med. 2016;194(8):1029-31. 378 
14. Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, et al. Treatment Outcomes 379 
in Multidrug-Resistant Tuberculosis. N Engl J Med. 2016;375(11):1103-5. 380 
15. Olaru ID, Lange C, Indra A, Meidlinger L, Huhulescu S, Rumetshofer R. High Rates of 381 
Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored 382 
Treatment Regimens. Ann Am Thorac Soc. 2016;13(8):1271-8. 383 
16. Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for 384 
treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3). 385 
21 
 
17. Olaru ID, Lange C, Heyckendorf J. Personalized medicine for patients with MDR-TB. J 386 
Antimicrob Chemother. 2016;71(4):852-5. 387 
18. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. 388 
Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J. 2015;45(4):1119-31. 389 
19. Pankhurst LJ, del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, et al. Rapid, 390 
comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a 391 
prospective study. The Lancet Respiratory Medicine. 2016;4(1):49-58. 392 
20. Votintseva AA, Bradley P, Pankhurst L, Del Ojo Elias C, Loose M, Nilgiriwala K, et al. 393 
Same-Day Diagnostic and Surveillance Data for Tuberculosis via Whole-Genome Sequencing 394 
of Direct Respiratory Samples. J Clin Microbiol. 2017;55(5):1285-98. 395 
21. Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, et al. A 396 
simple, valid, numerical score for grading chest x-ray severity in adult smear-positive 397 
pulmonary tuberculosis. Thorax. 2010;65(10):863-9. 398 
22. Rudolf F, Joaquim LC, Vieira C, Bjerregaard-Andersen M, Andersen A, Erlandsen M, et 399 
al. The Bandim tuberculosis score: reliability and comparison with the Karnofsky 400 
performance score. Scand J Infect Dis. 2013;45(4):256-64. 401 
23. Horsburgh CR, Jr., Barry CE, 3rd, Lange C. Treatment of Tuberculosis. N Engl J Med. 402 
2015;373(22):2149-60. 403 
24. World Health Organization. Companion handbook to the WHO guidelines for the 404 
programmatic management of drug-resistant tuberculosis. Geneva, Switzerland 2014. 405 
25. Schaberg T, Bauer T, Castell S, Dalhoff K, Detjen A, Diel R, et al. [Recommendations 406 
for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. 407 
German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. 408 
Pneumologie. 2012;66(3):133-71. 409 
26. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. 410 
Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients 411 
with multidrug-resistant tuberculosis: a secondary analysis of data from two observational 412 
cohort studies. Lancet Respir Med. 2015;3(3):201-9. 413 
27. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-414 
Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 415 
2012;366(23):2151-60. 416 
28. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. 417 
Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 418 
2014;371(8):723-32. 419 
29. Diacon AH, Van Baelen B, Theeuwes M. More on Treatment Outcomes in Multidrug-420 
Resistant Tuberculosis. N Engl J Med. 2016;375(26):2609-10. 421 
30. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly 422 
effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J 423 
Respir Crit Care Med. 2010;182(5):684-92. 424 
31. Günther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, et al. Beyond 425 
multidrug-resistant tuberculosis in Europe: a TBNET study. Int J Tuberc Lung Dis. 426 
2015;19(12):1524-7. 427 
32. Gunther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, et al. Multidrug-428 
resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis. 2015;21(3):409-16. 429 
33. Gao J, Ma Y, Du J, Zhu G, Tan S, Fu Y, et al. Later emergence of acquired drug 430 
resistance and its effect on treatment outcome in patients treated with Standard Short-431 
Course Chemotherapy for tuberculosis. BMC Pulm Med. 2016;16:26. 432 
22 
 
34. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment 433 
outcomes among patients with multidrug-resistant tuberculosis : systematic review and 434 
meta-analysis. The Lancet Infectious Diseases. 2009;9(3):153-61. 435 
35. Pinto LM, Pai M, Dheda K, Schwartzman K, Menzies D, Steingart KR. Scoring systems 436 
using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a 437 
systematic review. Eur Respir J. 2013;42(2):480-94. 438 
36. Rudolf F, Lemvik G, Abate E, Verkuilen J, Schon T, Gomes VF, et al. TBscore II: refining 439 
and validating a simple clinical score for treatment monitoring of patients with pulmonary 440 
tuberculosis. Scand J Infect Dis. 2013;45(11):825-36. 441 
37. Rudolf F, Wagner AJ, Back FM, Gomes VF, Aaby P, Ostergaard L, et al. Tuberculosis 442 
case finding and mortality prediction: added value of the clinical TBscore and biomarker 443 
suPAR. Int J Tuberc Lung Dis. 2017;21(1):67-72. 444 
38. Heyckendorf J, Olaru ID, Ruhwald M, Lange C. Getting personal perspectives on 445 
individualized treatment duration in multidrug-resistant and extensively drug-resistant 446 
tuberculosis. Am J Respir Crit Care Med. 2014;190(4):374-83. 447 
 448 
